Name | 4-(2-Hydroxy-2-propanyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazole-5-carboxylic acid |
Synonyms | CS 088 CS-415 Olmesartan Olmesartan Acid Olmesartan Medoxomil-1 Olmesartan (Olmesartan Medoxomil EP Impurity A) 4-(2-Hydroxy-2-propanyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazole-5-carboxylic acid 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid 1H-Imidazole-5-carboxylicacid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- |
CAS | 144689-24-7 |
EINECS | 646-413-5 |
InChI | InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29) |
Molecular Formula | C24H26N6O3 |
Molar Mass | 446.5 |
Density | 1.33 |
Melting Point | 186-188°C |
Boling Point | 738.3±70.0 °C(Predicted) |
Flash Point | 400.3°C |
Solubility | Soluble in DMSO (20 mM), methanol (sparingly), and tetrahydrofuran. |
Vapor Presure | 6.89E-23mmHg at 25°C |
Appearance | White solid |
Color | white to beige |
pKa | 2.39±0.50(Predicted) |
Storage Condition | 2-8°C |
Stability | Hygroscopic |
Refractive Index | 1.671 |
Use | An angiotensin II (AT1) receptor antagonist |
In vivo study | Repeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species. |
RTECS | NI4014100 |
HS Code | 29339900 |
overview | olmesartan is olmesartan medoxomil EP impurity a. Olmesartan medoxomil is a new angiotensin (AT) receptor antagonist, which was first approved by the US FDA for the treatment of hypertension in May 2002. |
biological activity | Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist, commonly used in hypertension related research. |
Cell Line: | Human cervical cancer cell line (HeLa) |
Concentration: | 0.7- 5 mM |
Incubation Time: | 24, 48 and 72 h |
Result: | IC 50 s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively. |
use | hypertension. among all kinds of drugs for treating hypertension, ARB has become the drug with the fastest increase in application ratio. the important reason is the effectiveness and good safety of these drugs (except pregnant women) |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |